2021年获批新药迷你回顾

Japan Journal of Clinical & Medical Research Pub Date : 2022-04-30 DOI:10.47363/jjcmr/2022(2)131

Akash Agnihotri, Saravana Kumar Ramasubbu

{"title":"2021年获批新药迷你回顾","authors":"Akash Agnihotri, Saravana Kumar Ramasubbu","doi":"10.47363/jjcmr/2022(2)131","DOIUrl":null,"url":null,"abstract":"In 2021, the US Food and Drug Administration approved 50 novel drugs. Twenty three of the 50 (46%) drugs were categorized as orphan drug, and 9 of the 50 (18%) were approved under accelerated approval. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2021","PeriodicalId":415591,"journal":{"name":"Japan Journal of Clinical & Medical Research","volume":"93 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A Mini Review on New Drugs Approved in 2021\",\"authors\":\"Akash Agnihotri, Saravana Kumar Ramasubbu\",\"doi\":\"10.47363/jjcmr/2022(2)131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In 2021, the US Food and Drug Administration approved 50 novel drugs. Twenty three of the 50 (46%) drugs were categorized as orphan drug, and 9 of the 50 (18%) were approved under accelerated approval. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2021\",\"PeriodicalId\":415591,\"journal\":{\"name\":\"Japan Journal of Clinical & Medical Research\",\"volume\":\"93 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japan Journal of Clinical & Medical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47363/jjcmr/2022(2)131\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japan Journal of Clinical & Medical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47363/jjcmr/2022(2)131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

2021年，美国食品和药物管理局批准了50种新药。50种药物中有23种(46%)被归类为孤儿药，50种药物中有9种(18%)以加速审批方式获得批准。本综述包括2021年美国食品和药物管理局批准的新药摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

A Mini Review on New Drugs Approved in 2021

In 2021, the US Food and Drug Administration approved 50 novel drugs. Twenty three of the 50 (46%) drugs were categorized as orphan drug, and 9 of the 50 (18%) were approved under accelerated approval. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2021

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Japan Journal of Clinical & Medical Research

自引率

0.00%

发文量